VIDEO: ALASCCA trial uses large dose of aspirin in colorectal cancer treatment
In this video, Michael Cecchini, MD, discussed data from the ALASCCA trial, which followed patients with colorectal cancer who were treated with a large dose of aspirin.
The large randomized clinical trial looked at a 160 mg dose of aspirin and showed a 50% reduction recurrence in stage II and III colorectal patients.
“The challenge here is, in reality, we are not doing tumor sequencing on these patients. So we don’t know who has the PIK3CA mutation in the adjuvant setting,” Cecchini, an associate professor of medical oncology at Yale School of Medicine, said. “So, I think there'll need to be some changes in in how we can actually select the patients in the United States and how reimbursement would work for us to be able to adopt something like this in practice.”
Collapse
Read more about